Long-Term Follow-Up Study of Participants Enrolled in the MGT016 Phase 1, Open-Label, Dose-Escalation Study of AAV2hAQP1 for Radiation-Induced Parotid Gland Hypofunction and Xerostomia
Latest Information Update: 22 Apr 2024
At a glance
- Drugs AAV AQP1 (Primary)
- Indications Xerostomia
- Focus Adverse reactions
- Sponsors MeiraGTx
- 15 Apr 2024 Planned End Date changed from 1 Nov 2027 to 1 Mar 2027.
- 15 Apr 2024 Planned primary completion date changed from 1 Nov 2026 to 1 Mar 2027.
- 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.